You are here: Home » Markets » News
Business Standard

Lupin gains 3% on USFDA approval for generic Corgard tablets

The company has received final approval from the US health regulator to market generic Nadolol tablets, used for treatment of hypertension, in the American market.

SI Reporter  |  Mumbai 

Pharmaceutical tablets and capsules

was trading 3% higher at Rs 1,068 on BSE at 09:30 AM after the pharmaceutical company said it has received final approval from the US health regulator to market generic Nadolol tablets, used for treatment of hypertension, in the American market.

“The company has received final approval for its Nadolol tablets USP 20 mg, 40 mg and 80 mg from the United States Food and Drug Administration (USFDA) to market a generic version of US WorldMeds, LLC Corgard Tablets, 20 mg, 40 mg and 80 mg,” said in a press release on Monday after market hours.

The product is a generic version of US WorldMeds LLC's in the same strengths, it added.

The tablets are indicated for management of patients with angina pectoris and for the treatment of hypertension.

According to IMS MAT June 2017 data, Nadolol tablets USP had annual sales of approximately USD 109.8 million in the US.

First Published: Tue, October 10 2017. 09:37 IST
RECOMMENDED FOR YOU